Clinical Trial Update: Venetoclax-Navitoclax With Cladribine-based Salvage Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating venetoclax and navitoclax with cladribine-based salvage therapy for relapsed/refractory acute myeloid leukemia has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Cladribine (cladribine)
• Navitoclax (navitoclax)
• Venetoclax (venetoclax)

Snippet

Sponsor: Medical College of Wisconsin | Conditions: Relapsed Adult AML, Refractory AML | Phase 1 | Status: WITHDRAWN